Oxidative stress and hypoxia in normal and leukemic stem cells

Area of Science:

• Hematology
• Cancer Biology
• Metabolic Regulation

Background:

• Hematopoietic stem cell (HSC) functions like self-renewal and differentiation are regulated by intrinsic and extrinsic factors.
• Cellular metabolism plays a critical role in HSC biology, with distinct pathways differing between stem cells and their progeny.
• Hypoxia is a key regulator, maintaining HSC quiescence through anaerobic glycolysis and low reactive oxygen species (ROS) production.

Purpose of the Study:

• To explore the emerging role of cellular metabolism in regulating hematopoietic stem cell (HSC) functions.
• To investigate the metabolic differences between normal HSCs and leukemic stem cells (LSCs) in acute myeloid leukemia (AML).
• To identify potential therapeutic targets within the metabolic pathways of LSCs.

Main Methods:

• Comparative analysis of metabolic pathways in HSCs, progenitors, and differentiated cells.
• Investigation of hypoxia-induced factors and their role in HSC quiescence and metabolism.
• Examination of mitochondrial function and metabolic properties of AML cells and LSCs.
• Analysis of IDH2 mutations in AML and their oncogenic role.

Main Results:

• HSCs maintain quiescence via anaerobic glycolysis, low ROS, and high antioxidant defense, while differentiation involves increased oxidative metabolism and ROS.
• Leukemic stem cells (LSCs) in AML show increased dependence on oxidative respiration over glycolysis and are more sensitive to oxidative stress.
• Mitochondrial abnormalities in AML cells contribute to aerobic glycolysis and present therapeutic opportunities.
• Mutations in isocitrate dehydrogenase-2 (IDH2) are oncogenic drivers in AML and are targets for specific inhibitors.

Conclusions:

• Cellular metabolism is a critical determinant of HSC function and dysregulation in AML.
• LSCs possess unique metabolic vulnerabilities that can be exploited for targeted therapies.
• Targeting metabolic pathways, including those affected by IDH2 mutations, offers a promising therapeutic strategy for AML.